Pomalyst vs revlimid

vs 7%), and weight decreased (20% vs 15%). DRUG INTERACTIONS. Periodically REVLIMID, POMALYST, POMALYST REMS, IMiD, and associated logos are

Revlimid) with broader biological activity [than Revlimid/Pomalyst]. and helpful resources and events with cancer experts. subscribe

Pomalyst has shown efficacy in patients not responding to Revlimid, and in Revlimid-resistant cell lines and animal models. Although both

announced that Health Canada approved a Pomalyst (pomalidomide)-based triplet combination with bortezomib and Revlimid (lenalidomide)

MM009 and MM010, in which Revlimid dexamethasone was compared to ▫ Understanding POMALYST (pomalidomide). ▫ Understanding REVLIMID

Prescribing information ; POMALYST Patient information Prescribing information ; REVLIMID Patient information Prescribing information.

Novem – The FDA approved an update to the Warnings and Precautions section of the Pomalyst (pomalidomide), Revlimid

POMALYST with dexamethasone is proven to continue the fi g h t if multiple myeloma stops responding to REVLIMID and a PI POMALYST has immune-modulating qualities similar to REVLIMID POMALYST is a once-daily capsule, not an injection or infusion If multiple myeloma (MM) stops responding to REVLIMID

financial resources including co-pay assistance for patients taking POMALYST for REVLIMID and POMALYST including Boxed WARNINGS. Please read Patient